Genentech, Roche Subsidiary, Breaks Ground on $700M Manufacturing Facility in North Carolina
Genentech, a member of Roche Holding AG, has recently commenced construction on a cutting-edge manufacturing facility in Holly Springs, North Carolina. This significant $700 million project is part of Roche's substantial $50 billion investment in U.S. manufacturing, infrastructure, and R&D. The facility will focus on producing next-generation metabolic medicines, including treatments for obesity, and is expected to generate over 1,900 jobs. The site, strategically located in a biopharmaceutical innovation hub, is designed for high-volume, efficient, and sustainable production and is set to be operational by 2029. This development underscores Roche's commitment to delivering life-changing treatments to patients more efficiently and expanding its U.S. presence.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001124582-en) on August 25, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。